Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › epithelial ovarian cancer

Epithelial ovarian cancer

Part of Adnexal Diseases

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for epithelial ovarian cancer

30 trials tracked for epithelial ovarian cancer: 6 in phase 3 or 4 and 5 with published results. The most-cited published study has 438 citations.

30Trials tracked
6Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 3 6 Phase 2 17 Phase 1 4 Other / NA 3
  1. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression Completed · 438 cited
  2. Phase 3 A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Completed · 375 cited
  3. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer Completed · 295 cited
  4. Phase 3 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Completed · 143 cited
  5. Phase 3 A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. Completed · 108 cited
  6. Phase 3 CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib Completed
Show 24 more trials
  1. Phase 2 A Study LY2228820 for Recurrent Ovarian Cancer Completed
  2. Phase 2 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Completed
  3. Phase 2 A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers Completed
  4. Phase 2 RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) Completed
  5. Phase 2 A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer Completed
  6. Phase 2 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Completed
  7. Phase 2 Neoadjuvant Therapy for Ovarian Cancer Completed
  8. Phase 2 Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer Completed
  9. Phase 2 Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab Completed
  10. Phase 2 A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment Completed
  11. Phase 2 Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer Completed
  12. Phase 2 Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors Completed
  13. Phase 2 Ovarian Cancer Vaccine for Patients in Remission Completed
  14. Phase 2 Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study Completed
  15. Phase 2 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer Completed
  16. Phase 2 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed
  17. Phase 2 Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer Completed
  18. Phase 1 Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers Completed
  19. Phase 1 Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed
  20. Phase 1 A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers Completed
  21. Phase 1 Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed
  22. N/A Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study Completed
  23. N/A Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation Completed
  24. N/A Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand Completed

Showing the 30 most-cited and recently-updated of 30 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Epithelial ovarian cancer: what the trials found

New evidence indicates that Rucaparib demonstrated superior progression-free survival (PFS) compared to chemotherapy in both efficacy and ITT populations (p=0.0010; p=0.0017), with a significantly longer duration of response (DOR) (p=0.0401) 5. Additionally, Rucaparib was evaluated in several other clinical contexts [1, 7].

Mirvetuximab soravtansine showed significant improvements in progression-free survival (PFS) compared to standard care (p<0.0001) 2, with objective response rates (ORR) ranging from 22% to 50% across different study cohorts [3, 4]. In dose expansion studies, Mirvetuximab soravtansine demonstrated ORRs of up to 83% in specific regimens 10.

Olaparib was shown to provide a statistically significant improvement in progression-free survival (PFS) compared to its active comparator (p=0.0220) 6.

Recent results — preliminary, needs further review

  • Ixabepilone combined with Bevacizumab showed superior progression-free survival (PFS) (p<0.001), objective response rate (ORR) (p=0.003), and overall survival (OS) (p=0.018) compared to Ixabepilone alone 9.

For the clinician treating this condition

  • Rucaparib is associated with superior progression-free survival and longer duration of response compared to chemotherapy 5.
  • Mirvetuximab soravtansine demonstrates significant improvements in progression-free survival and high objective response rates in specific patient populations [2, 10].
  • Olaparib provides a statistically significant improvement in progression-free survival over its active comparator 6.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Omics-guided surgical paradigms may identify specific patients for selective retroperitoneal clearance in advanced ovarian cancer
Oncology Sys. Review
Omics-guided surgical paradigms may identify specific patients for selective retroperitoneal clearance in advanced ovarian cancer New Surgical Approach May Reduce Risks for Ovarian Cancer Patients
This systematic review examines the role of omics-guided surgery versus routine lymphadenectomy in advanced epithelial ovarian cancer. The a…
A new surgical model aims to reduce complications and identify specific patients who may benefit from targeted treatments for advanced ovari…
Frontiers Jul 10, 2026
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
Oncology RCT
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
Apr 23, 2026

Research across Adnexal Diseases

Related studies from across the Adnexal Diseases family.

Narrative review links lactylation modification to gynecological disease pathogenesis and potential therapy
OB/GYN & Women's Health Meta-analysis
Narrative review links lactylation modification to gynecological disease pathogenesis and potential therapy New metabolic switch could help treat difficult gynecological conditions
This narrative review addresses the lack of systematic analysis on lactylation modification in gynecological diseases. The authors synthesiz…
A new cellular switch that uses energy to control genes might one day help doctors treat difficult gynecological conditions like endometrios…
Frontiers May 4, 2026
Systematic review and meta-analysis on LH-active gonadotropins for ovarian stimulation in infertility
Diabetes & Endocrinology Meta-analysis
Systematic review and meta-analysis on LH-active gonadotropins for ovarian stimulation in infertility Adding LH-active hormone to fertility treatment doesn't boost live births
This meta-analysis of 56 RCTs with 14,034 women found little to no difference in live birth or ongoing pregnancy when adding LH-active gonad…
For women using fertility drugs, adding LH doesn't improve live birth or pregnancy odds, but it may slightly lower egg yield without raising…
Frontiers Apr 22, 2026
Residence in mining districts associated with higher hospitalization rates for uterine and ovarian pathologies among gynecological inpatients
OB/GYN & Women's Health Cohort
Residence in mining districts associated with higher hospitalization rates for uterine and ovarian pathologies among gynecological inpatients Mining Towns See More Gynecology Visits
This retrospective cross-sectional study examined 4,935 gynecological inpatients at a tertiary hospital in Heilongjiang Province, China.
Women in China's mining towns face higher rates of gynecological issues like fibroids and polyps, with hospitalization rates nearly five tim…
Frontiers Apr 20, 2026
Network meta-analysis finds GnRHa trigger reduces OHSS risk versus hCG in predicted high responders undergoing IVF
Diabetes & Endocrinology Meta-analysis
Network meta-analysis finds GnRHa trigger reduces OHSS risk versus hCG in predicted high responders undergoing IVF Study compares four IVF trigger methods for women at high risk of over-response
A network meta-analysis of 7 RCTs involving 632 predicted high responders undergoing IVF with GnRH antagonist protocols compared four final …
For women at high risk of painful IVF complications, a specific hormone trigger shot significantly lowers that risk without reducing egg cou…
Frontiers Apr 8, 2026